2016 American Transplant Congress
An Evaluation of the Safety, Efficacy, and Pharmacoeconomics of Two Valganciclovir Prophylaxis Regimens Following Renal Transplantation.
1IU Health, University Hospital, Indianapolis, IN; 2Butler University, Indianapolis, IN.
Valganciclovir is the preferred prophylactic therapy for the prevention of CMV in transplant recipients and is the most expensive medication required post transplantation. The objective…2016 American Transplant Congress
Is CMV Prophylaxis Effective in CMV-Seropositive Patients Receiving Thymoglobulin as Induction Therapy?
Kidney Transplantation Service, Hospital das Clinicas - University of Sao Paulo, Sao Paulo, Brazil.
Thymoglobulin (ATG) used as induction therapy is considered a risk factor for CMV disease in renal transplantation (RTx) and prophylaxis is recommended. Our center policy…2015 American Transplant Congress
Recipient Immunity to Murine Cytomegalovirus Influences Natural Killer Cell Responses in Infected Renal Allografts
BACKGROUND: Human cytomegalovirus (CMV) is associated epidemiologically with renal allograft loss, but the impact of recipient CMV immunity upon graft survival is unclear. Natural killer…2015 American Transplant Congress
Recurrent Cytomegalovirus Infection After Solid Organ Transplant
University Health Network, Toronto, Canada.
Background:Cytomegalovirus is a common opportunistic infection after transplant. Relapse may occur after treatment of the initial episode of viremia or disease and secondary prophylaxis is…2015 American Transplant Congress
Epigenetic Reprogramming of Murine Cytomegalovirus Immediate Early Genes Induced By Renal Transplantation
Background: Reactivation of latent CMV is a significant infectious complication in solid organ transplant recipients. MCMV is a valuable model for studying molecular mechanisms controlling…2015 American Transplant Congress
Safety and Outcome of Ganciclovir-Resistant CMV Treated With Foscarnet: A Single Center Retrospective Study
Background: Infection with cytomegalovirus (CMV) is an important cause of morbidity and mortality following solid organ transplantation (SOT). Resistance can rarely develop via mutations in…2015 American Transplant Congress
A Prospective Pilot Study Evaluating the Safety and Efficacy of Everolimus for the Prevention of CMV and BK Viral Infection (BKV) in Broadly Sensitized Kidney Transplant Recipients Following Desensitization With IVIG and Rituximab: Interim Analysis
Introduction: Everolimus, a second generation mTOR inhibitor, may prevent CMV and BKV infection after kidney transplantation. Broadly sensitized patients are at greater risk of viral…2015 American Transplant Congress
Implementation of Evidence-Based Guidelines for Cytomegalovirus Prevention in Pediatric Solid Organ Transplantation
Cincinnati Children's, Cincinnati.
Optimal strategies to prevent cytomegalovirus (CMV) disease after pediatric solid organ transplantation (SOT) in a cost effective manner are uncertain. We evaluated the frequency of…2015 American Transplant Congress
Viral Prophylaxis Is Unnecessary in CMV Low Risk Kidney Transplant Recipients Who Receive Lymphocyte Depleting Induction
Background: Both the international CMV consensus and AST guidelines recommend against the routine use of CMV prophylaxis in CMV D-/R- kidney transplant recipients (KTR), but…2015 American Transplant Congress
Incidence and Characteristics of CMV Infection in High Risk (D+R-) Kidney Transplant Recipients and the Utility of Monthly Surveillance After Routine Prophylaxis
Internal Medicine, University of Pittsburgh, Pittsburgh, PA.
Cytomegalovirus (CMV) infection is the most common opportunistic viral infection after renal transplantation. Optimal duration of antiviral prophylaxis and the role of post prophylaxis surveillance…
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- 33
- Next Page »